The journal of gene medicine.
Publisher:
John Wiley & Sons,
Frequency: Bimonthly
Country: England
Language: English
Start Year:1999 -
ISSN:
1099-498X (Print)
1521-2254 (Electronic)
1099-498X (Linking)
1521-2254 (Electronic)
1099-498X (Linking)
Impact Factor
3.5
2022
| NLM ID: | 9815764 |
| (OCoLC): | 39136900 |
| (DNLM): | SR0093581(s) |
| Coden: | JGMEFG |
| LCCN: | sn 98000658 |
| Classification: | W1 JO6637 |
Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment. A combination of tissue engineering methods employing mesenchymal stem cells (MSCs) together with gene transfer takes advantage of innovative strategies and highlights a new approach for targeting osteoarthritis (OA) and other cartilage defects. Furthermore, the development of systems allowing tunable transgene expression as regulated by natural disease-induced substances is highly desirable. Bone marrow-derived equine MSCs were transduced with a lentiviral vector expressing interleukin-1 receptor antagonist (IL-1Ra) gene under the control of an inducible nuclear factor-kappa B-responsive prom...
Inflammation-induced transgene expression in genetically engineered equine mesenchymal stem cells. Osteoarthritis, a chronic and progressive degenerative joint disorder, ranks amongst the top five causes of disability. Given the high incidence, associated socioeconomic costs and the absence of effective disease-modifying therapies of osteoarthritis, cell-based treatments offer a promising new approach. Owing to their paracrine, differentiation and self-renewal abilities, mesenchymal stem cells (MSCs) have great potential for regenerative medicine, which might be further enhanced by targeted gene therapy. Hence, the development of systems allowing transgene expression, particularly when regu...
Plasmid growth hormone releasing hormone therapy in healthy and laminitis-afflicted horses-evaluation and pilot study. In vivo electroporation dramatically improves the potency of plasmid-mediated therapies, including in large animal models. Laminitis and arthritis are common and debilitating diseases in the horse, as well as humans. Methods: The effects of growth hormone releasing hormone (GHRH) on healthy horses and on horses with laminitis that were followed for 6 months after a single intramuscular injection and electroporation of 2.5 mg of an optimized myogenic GHRH-expressing plasmid were examined. Results: In the first study on six healthy horses, we observed a significant increase in body mass by day 1...